Skip to main content

Advertisement

SpringerLink
Log in

Dementia and Overactive Bladder

  • Overactive Bladder (A Klausner, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) and urinary incontinence are common in patients with dementia. The etiology is likely multifactorial making it very challenging to treat. Furthermore, the use of anticholinergics, the mainstay of medical management of OAB, in patients with dementia is controversial. The optimal treatment strategy requires setting realistic goals and communicating with family members and care providers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hellstrom L, Ekelund P, Milsom I, et al. The influence of dementia on the prevalence of urinary and fecal incontinence in 85-year-old men and women. Arch Gerontol Geriatr. 1994;19:11–20.

    Article  PubMed  CAS  Google Scholar 

  2. O’Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992;5:45–52.

    PubMed  Google Scholar 

  3. Resnick NM, Yalla SV, Laurino MS. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med. 1989;320:1–7.

    Article  PubMed  CAS  Google Scholar 

  4. Mori S, Kojima M, Sakai Y, et al. Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride. Nihon Ronen Igakkai Zasshi. 1999;36:489–94.

    Article  PubMed  CAS  Google Scholar 

  5. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology. 2002;60:50–5.

    Article  PubMed  Google Scholar 

  6. Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: an unrecognized adverse effect with donepezil. Lancet. 2000;356:568.

    Google Scholar 

  7. Starr JM. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer’s disease. J Am Geriatr Soc. 2007;55:800–1.

    Article  PubMed  Google Scholar 

  8. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165:808–13.

    Article  PubMed  Google Scholar 

  9. Sink KM, Thomas J, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56:847–53.

    Article  PubMed  Google Scholar 

  10. Jirovec MM, Wells TJ. Urinary incontinence in nursing home residents with dementia: the mobility-cognition paradigm. Appl Nurs Res. 1990;3:112–7.

    Article  PubMed  CAS  Google Scholar 

  11. Ouslander JG, Uman GC, Urman NH, et al. Incontinence among nursing home patients: clinical and functional correlates. J Am Geriatr Soc. 1987;35:324–30.

    PubMed  CAS  Google Scholar 

  12. Yap P, Tan D. Urinary incontinence in dementia-a practical approach. Aust Fam Physician. 2006;35:237–41.

    PubMed  Google Scholar 

  13. Resnick NM, Yalla SV. Current concepts: management of urinary incontinence in the elderly. N Engl J Med. 1985;313:800–15.

    Article  PubMed  CAS  Google Scholar 

  14. Lee CY, Chen LK, Lo YK, et al. Urinary incontinence: an under-recognized risk factor for fall among elderly dementia patients. Neurourol Urodynam. 2011;30:1286–90.

    Article  Google Scholar 

  15. Schnelle JF, Alessi CA, Simmon SF. Translating clinical research into practice: a randomized controlled trial of exercise and incontinence care with nursing home residents. J Am Geriatr Soc. 2002;50:1476–83.

    Article  PubMed  Google Scholar 

  16. Specht JK. Promoting continence in individuals with dementia. J Gerontol Nurs. 2011;37:17–21.

    Article  PubMed  Google Scholar 

  17. Goode PS, Burgio KL, Richter HE, et al. Incontinence in older women. JAMA. 2010;303:2171–81.

    Article  Google Scholar 

  18. Lancioni GE, Singh NN, O’Reilly MF, et al. Persons with mild or moderate Alzheimer’s disease learn to use urine alarms and prompts to avoid large urinary accidents. Res Dev Disabil. 2011;32:1998–2004.

    Article  PubMed  Google Scholar 

  19. Tannebaum C, DuBeau CE. Urinary incontinence in the nursing home: practical approach to evaluation and management. Clin Geriatr Med. 2004;20:437–52.

    Article  Google Scholar 

  20. Ouslander JG, Schnelle JF, Uman G, et al. Predictors of successful prompted voiding among incontinent nursing home residents. JAMA. 1995;273:1366–70.

    Article  PubMed  CAS  Google Scholar 

  21. Lekan-Rutledge D. Diffusion of innovation. A model for implementation of prompted voiding in long-term care settings. J Gerontol Nurs. 2000;26:25–33.

    PubMed  CAS  Google Scholar 

  22. Kyle G. An insight into continence management in patients with dementia. Br J Community Nurs. 2012;17:125–31.

    PubMed  Google Scholar 

  23. • Paquette A, Gou P, Tannebaum C. Systematic review and metanalysis: do Clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332–9. This study draws attention to the fact that current clinical trials evaluating anticholinergics do not adequately evaluate for or report CNS side effects.

    Article  PubMed  Google Scholar 

  24. Kay GG, Mohamed B, Abou-Donia MB, Messer WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function. J Am Geriatr Soc. 2005;53:2195–201.

    Article  PubMed  Google Scholar 

  25. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br Pharmacol. 2006;148:565–78.

    Article  CAS  Google Scholar 

  26. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol. 2002;22:133–45.

    Article  PubMed  CAS  Google Scholar 

  27. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581–631.

    Article  PubMed  CAS  Google Scholar 

  28. Hedge SS, Choppin A, Bonhaus D. Functional role of M2 and M3 muscarini receptors in the urinary bladder of rates in vitro and in vivo. Br J Pharmacol. 1997;120:1409–18.

    Article  Google Scholar 

  29. • Pagoria D, O’Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011;12:351–7. This article reviews the limited data regarding the cognitive side effects of individual anticholinergics in elderly patients as well as some of the factors that contribute to the increased susceptibility of the elderly to cognitive impairment.

    Article  PubMed  Google Scholar 

  30. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62:1792–800.

    Article  PubMed  CAS  Google Scholar 

  31. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50:317–26.

    Article  PubMed  CAS  Google Scholar 

  32. Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment of sedation in the elderly following single doses of solifenacin 10 mg. Epert Opin Drug Saf. 2009;8:615–26.

    Article  CAS  Google Scholar 

  33. •• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18:167–74. This article reviews data on the CNS side effects associated with anticholinergics used for OAB and the pharmacologic properties that affect the propensity of various agents to cause cognitive side effects.

    Article  PubMed  CAS  Google Scholar 

  34. Lackner TE, Wyman JF, Mccarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56:862–70.

    Article  PubMed  Google Scholar 

  35. Katz IR, Sand LP, Bilker W. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13.

    PubMed  CAS  Google Scholar 

  36. Salvatore S, Serati M, Cardozo L. Cognitive dysfunction with tolterodine use. Am J Obstet Gynecol. 2007;197:e8.

    Article  PubMed  Google Scholar 

  37. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol. 2003;60:771–3.

    Article  PubMed  Google Scholar 

  38. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of elderly population: effects of darifenacin. J Urol. 2005;173:493–8.

    Article  PubMed  Google Scholar 

  39. Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory resting and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64:1294–300.

    Article  PubMed  CAS  Google Scholar 

  40. Jewart RD, Green J, Lu DJ, et al. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry. 2005;13:324–8.

    PubMed  Google Scholar 

  41. Oulsander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc. 1995;43:610–7.

    Google Scholar 

  42. Ouslander JG, Blaustein J, Conor A, et al. Habit training and oxybutynin for incontinence in nursing home patients: a placebo controlled study. J Am Geriatr Soc. 1988;36:40–6.

    PubMed  CAS  Google Scholar 

  43. Carnahan RM, Lund BC, Perry PJ, et al. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004;52:2082–7.

    Article  PubMed  Google Scholar 

  44. Sakakibara R, Uchiyama T, Yamanishi T, et al. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Intl J Uorl. 2008;15:778–88.

    Article  Google Scholar 

  45. Edwards KR, O’Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc. 2002;50:1165–6.

    Article  PubMed  Google Scholar 

  46. Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer’s disease. Psychiatr. 2003;11-458-61.

    Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. University of Kentucky, 800 Rose Street, Rm MS269, Lexington, KY, 40536, USA

    Katie N. Ballert

  2. The University of Chicago Medicine & Biological Sciences, 5841 South Maryland Avenue, Rm J-653, MC6038, Chicago, IL, 60637, USA

    Gregory T. Bales

Authors
  1. Katie N. Ballert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory T. Bales
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katie N. Ballert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ballert, K.N., Bales, G.T. Dementia and Overactive Bladder. Curr Bladder Dysfunct Rep 8, 57–61 (2013). https://doi.org/10.1007/s11884-012-0171-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-012-0171-6

Keywords

Search

Navigation